News Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Mar 05, 2019Fourth Quarter U.S. Laser Revenue Increased 51% Year Over Year
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today reported net revenue of $13.0 million and $46.2 million for the fourth quarter and year ended December 31, 2018,...
- Mar 04, 2019Proven C-Suite Executive Brings Extensive Healthcare Industry Experience to New Role
FARMINGDALE, N.Y., March 04, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices...
- Mar 04, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has filed a New Drug Submission (“NDS”) for Avanafil with...
- Feb 28, 2019FDA decision on AR101 BLA filing acceptance expected by end of March
BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 28, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Feb 28, 2019BIOLASE appoints Sinclair Dental, the fastest growing full-service dental supply company in Canada, as the exclusive distributor and representative for the sales, service and support of BIOLASE's products
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced the appointment of Sinclair Dental Co. Ltd, the fastest growing dental supply company in Canada with more than 600...
- Feb 27, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) announced today two updates relative to the Company’s NATESTO® business. First, the...
- Feb 26, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP) will announce financial results for the three and twelve month periods ending December 31, 2018 on Tuesday, March 05, 2019...
- Feb 25, 2019— AR101 Associated with 70% Reduction in Allergic Reactions Due to Accidental Exposures That Required Treatment Compared to Placebo After Dose Escalation in PALISADE —
BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 25, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Feb 25, 2019
FARMINGDALE, N.Y., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Feb 21, 2019
DEER PARK, Ill., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Feb 21, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 21, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Feb 19, 2019If Approved, EM-100 Will Be the First OTC Preservative-Free Formulation of Its Kind
LAVAL, Quebec and DEER PARK, Ill., Feb. 19, 2019 – Bausch Health Companies Inc. (NYSE/TSX: BHC) and Bausch + Lomb, its wholly owned subsidiary and a leading global eye health company, and Eton...
- Feb 13, 2019— Drug Development Advancing: Successful TADFIN Clinical Trial with NDA Filing in 2019; Two Prostate Cancer Clinical Trials Enrolling — — Company to Host Investor Conference Call on Wednesday, February 13, 2019, 8 a.m. ET —
MIAMI, Feb. 13, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and...
- Feb 12, 2019
MIAMI, Feb. 12, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and...
- Feb 11, 2019Transaction adds an additional potential 2019 product launch to Eton’s pipeline
DEER PARK, Ill., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Feb 07, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release fourth quarter 2018 financial and operating results on Tuesday, March 5, 2019 after the close...
- Feb 06, 2019
MIAMI, Feb. 06, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and...
- Feb 06, 2019
FARMINGDALE, N.Y., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Feb 04, 2019— Nine Abstracts Featured, Including Data on Longer-Term AR101 Efficacy and Safety and PALISADE Accidental Exposures —
BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 4, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Feb 04, 2019Feb. 4 event will include meet-and-greets with Dallas Mavericks players, Mavs ManiAACs, dancers, and families will learn more about the latest dental technologies, including laser treatments
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, the Dallas Mavericks and TeamSmile, the nation's premier advocacy group that supports life-changing dental care for underserved...
- Jan 29, 2019On the heels of a successful co-promotion during the recent Greater New York Dental Meeting, the two companies will offer exclusive deals and product samples for complimentary product lines at the Yankee Dental Congress and Chicago Midwinter Meeting
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today a joint product promotion with Hu-Friedy, the global leader in the manufacturing of dental instruments, at two...
- Jan 25, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX: ASP) (“Acerus” or the “Company”) is today advising that it has received a Notice of Deficiency-Withdrawal Letter...
- Jan 24, 2019New Drug Application expected to be filed in 2019
DEER PARK, Ill., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Jan 22, 2019–Open-Label Phase 1b/2 Clinical Trial Results Expected by Year-End– — Drug Addresses Significant Unmet Medical Need —
MIAMI, Jan. 22, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that it has initiated and enrolled the first patient in a...
- Jan 22, 2019
FARMINGDALE, N.Y., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...